This protocol addresses the specific situation where moderate to severe vasomotor symptoms — hot flashes — persist in a menopausal woman who has no uterus and no contraindication to estrogen therapy, and whose prior treatment with cognitive behavioural therapy did not achieve adequate symptom control.
The patient has moderate to severe hot flashes (vasomotor symptoms), absence of uterus, and no contraindication to estrogen therapy. This combination defines the population for this treatment line.
Cognitive behavioural therapy was the prior intervention, with the goal of reducing vasomotor symptoms (hot flashes). When that reduction is not achieved, escalation to a further management approach is indicated — this protocol defines that next step.
This line draws on complementary and alternative medicine options, including certain plant-derived compounds and herbal preparations. The efficacy of these approaches has not been definitively proven. The complete structured regimen — with the specific options and sequencing — is available below.
Moderate to severe hot flashes: MHT is the gold standard and best therapy for reduction of VMS (Tables 1-5), followed by non-hormonal prescription medications (Tables 6, 7) as a second choice.
Women without a uterus can use systemic estrogen-alone therapy (ET).
If these strategies are ineffective or unacceptable, complementary and alternative medicine may be used, although efficacy is unproven.
Phytoestrogens comprise two major categories: (1) isoflavones (particularly genistein), which have shown benefit in treating mild vasomotor symptoms, and (2) flaxseed, which has not.
St John's Wort has been shown to improve sleep and quality of life in menopausal women.
View source ↗